Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Yangwei Fan"'
Autor:
Yu Shi, Liankang Sun, Rui Zhang, Yuan Hu, Yinying Wu, Xuyuan Dong, Danfeng Dong, Chen Chen, Zhimin Geng, Enxiao Li, Yangwei Fan
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 40, Iss 1, Pp 1-19 (2021)
Abstract Background Cancer-associated fibroblasts (CAFs), the primary component of tumor stroma in tumor microenvironments, are well-known contributors to the malignant progression of gallbladder cancer (GBC). Thrombospondins (THBSs or TSPs) comprise
Externí odkaz:
https://doaj.org/article/0aa25359fd4740eabf3549a42c6f1d54
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 12 (2020)
Background: The evidence base for optimum third-line therapy for metastatic colorectal cancer (mCRC) is not conclusive. Recent studies have demonstrated the efficacy of regorafenib as third-line therapy in mCRC. This indirect meta-analysis compared t
Externí odkaz:
https://doaj.org/article/4f9ee2149765427592d2e570e32d19d8
Autor:
Ting Li, Jiang Guo, Yushen Liu, Zhaoqing Du, Zhaoyang Guo, Yangwei Fan, Long Cheng, Yue Zhang, Xu Gao, Yunyu Zhao, Xinyuan He, Wenhua Wu, Ning Gao, Yinying Wu, Jie Li, Yu Zhang, Wen Kang, Zhifang Cai, Wenjun Wang, Xiaopeng Li, Ying Zan, Mindie H. Nguyen, Fanpu Ji
Publikováno v:
Cancer Immunology, Immunotherapy.
There is a lack of effective programmed cell death protein 1 (PD-1)‐targeted immunotherapy with good tolerability in patients with advanced hepatocellular carcinoma (HCC) and severely compromised liver function. We assessed patient outcomes after c
Autor:
Danfeng Dong, Xuyuan Dong, Yangwei Fan, Yinying Wu, Pengchuang Zhang, Yu Shi, Jiayu Jing, Enxiao Li, Yuan Hu
Publikováno v:
Translational Cancer Research
Background Pancreatic cancer is generally characterized with high levels of malignancy and poor prognosis. In addition, there are currently no effective therapeutic agents against the disease. However, apatinib which is a small molecular agent target
Publikováno v:
Journal of Cancer
Chemotherapy resistance represents a major obstacle for the treatment of patients with breast cancer (BC) and greatly restricts the therapeutic effect of the first-line chemotherapeutic agent doxorubicin (DOX). The present study aimed to investigate
Autor:
Yinying Wu, Yuan Hu, Yu Shi, Xuyuan Dong, Danfeng Dong, Qianqian Geng, Enxiao Li, Yangwei Fan, Jiayu Jing, Chuying Wang
Publikováno v:
Journal of Cellular and Molecular Medicine
High rates of de novo lipid synthesis have been discovered in certain kinds of tumours, including gallbladder cancer (GBC). Unlike several other tumours, GBC is highly insensitive to standard adjuvant therapy, which makes its treatment even more chal
Autor:
Yangwei Fan, Yuan Hu, Xuyuan Dong, Yinying Wu, Danfeng Dong, Pengchuang Zhang, Yu Shi, Enxiao Li
Publikováno v:
Environmental toxicologyREFERENCES. 37(3)
Ras protein activator like 2 (RASAL2) has a cancer-related function, but plays inconsistent roles in different malignancies. This project was designed to determine the role of RASAL2 in carcinogenesis in gastric cancer. The Cancer Genome Atlas data r
Purpose: The electronic patient-reported outcome (ePRO) system plays an important role in routine cancer treatment, but information on its use to assess and monitor symptoms and quality of life (QoL) in advanced gastrointestinal cancer patients in Ch
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4391754767190d3e3cbee34bee9ca6ed
https://doi.org/10.21203/rs.3.rs-821631/v1
https://doi.org/10.21203/rs.3.rs-821631/v1
Autor:
Ting Li, Jiang Guo, Yushen Liu, Zhaoqing Du, Zhaoyang Guo, Yangwei Fan, Long Cheng, Yue Zhang, Xu Gao, Yunyu Zhao, Xinyuan He, Wenhua Wu, Ning Gao, Yinying Wu, Jie Li, Yu Zhang, Wen Kang, Zhifang Cai, Wenjun Wang, Xiaopeng Li, Ying Zan, Fanpu Ji
Publikováno v:
Gastroenterology. 162:S-1156
Publikováno v:
Cancer Biology & Therapy. 20:617-632
Triple-negative breast cancer (TNBC) has a poor prognosis mainly due to insensitivity or resistance to standard anthracycline- and taxane-based chemotherapy, urgently calling for new adjuvants to reverse drug resistance. Dual-target murine double min